White House bats down speculation that Trump got access to Eli Lilly obesity drug for ‘compassionate use’

Read full story on The Hill
Share
White House bats down speculation that Trump got access to Eli Lilly obesity drug for ‘compassionate use’
AI disclosure

Summary

White House officials on Tuesday shot down a report speculating that President Trump gained access to the retatrutide weight-loss drug under the Food and Drug Administration’s (FDA) “compassionate use program.” The retatrutide drug is manufactured by Eli Lilly and is not FDA approved, however, one person gained access to the prescription through a program that…

Original reporting

Open original source

Related coverage

Read full article on The Hill

Get the AFBytes Brief

Major stories, AI-assisted analysis, and what to watch next. Free, monthly, unsubscribe anytime.